There are 327 resources available
139O - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
140O - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial
Presenter: Jean-Pierre Ayoub
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
183O - Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)
Presenter: Antonio Di Meglio
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
1O - Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial
Presenter: Cristina Saura Manich
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
80O - Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
Presenter: Joyce O'Shaughnessy
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
2O - ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis
Presenter: Tomas Pascual
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
98O - The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)
Presenter: Nour Abuhadra
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
184O - The risk of late breast cancer recurrence in Denmark during 17 years of follow-up
Presenter: Rikke Pedersen
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
3O - Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Presenter: William Jacot
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
96O - Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE
Presenter: Sibylle Loibl
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast